186 related articles for article (PubMed ID: 31674861)
1. Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study).
Aihara M; Lu F; Kawata H; Tanaka Y; Yamamura K; Odani-Kawabata N; Shams NK
J Ocul Pharmacol Ther; 2019 Dec; 35(10):542-550. PubMed ID: 31674861
[No Abstract] [Full Text] [Related]
2. Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys.
Fuwa M; Shimazaki A; Odani-Kawabata N; Kirihara T; Taniguchi T; Iwamura R; Yoneda K; Kato M; Morishima K; Shams NK
J Ocul Pharmacol Ther; 2021 May; 37(4):223-229. PubMed ID: 33600237
[No Abstract] [Full Text] [Related]
3. Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study.
Aihara M; Ropo A; Lu F; Kawata H; Iwata A; Odani-Kawabata N; Shams N
Jpn J Ophthalmol; 2020 Jul; 64(4):398-406. PubMed ID: 32572719
[TBL] [Abstract][Full Text] [Related]
4. Human experience and efficacy of omidenepag isopropyl (Eybelis®; Omlonti®): Discovery to approval of the novel non-prostaglandin EP2-receptor-selective agonist ocular hypotensive drug.
Sharif NA
Curr Opin Pharmacol; 2024 Feb; 74():102426. PubMed ID: 38168596
[TBL] [Abstract][Full Text] [Related]
5. Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension.
Aihara M; Lu F; Kawata H; Iwata A; Liu K; Odani-Kawabata N; Shams NK
J Glaucoma; 2019 May; 28(5):375-385. PubMed ID: 30839416
[TBL] [Abstract][Full Text] [Related]
6. Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys.
Fuwa M; Toris CB; Fan S; Taniguchi T; Ichikawa M; Odani-Kawabata N; Iwamura R; Yoneda K; Matsugi T; Shams NK; Zhang JZ
J Ocul Pharmacol Ther; 2018 Sep; 34(7):531-537. PubMed ID: 29989843
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent.
Kirihara T; Taniguchi T; Yamamura K; Iwamura R; Yoneda K; Odani-Kawabata N; Shimazaki A; Matsugi T; Shams N; Zhang JZ
Invest Ophthalmol Vis Sci; 2018 Jan; 59(1):145-153. PubMed ID: 29332128
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Omidenepag Isopropyl 0.002% Ophthalmic Solution: A Retrospective Analysis of Real-World Data in Japan.
Miki A; Miyamoto E; Ishida N; Shii D; Hori K;
Adv Ther; 2022 May; 39(5):2085-2095. PubMed ID: 35287233
[TBL] [Abstract][Full Text] [Related]
9. Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension: The Phase 3 AYAME Study.
Aihara M; Lu F; Kawata H; Iwata A; Odani-Kawabata N; Shams NK
Am J Ophthalmol; 2020 Dec; 220():53-63. PubMed ID: 32533949
[TBL] [Abstract][Full Text] [Related]
10. Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study.
Aihara M; Lu F; Kawata H; Iwata A; Odani-Kawabata N
Jpn J Ophthalmol; 2021 Nov; 65(6):810-819. PubMed ID: 34495425
[TBL] [Abstract][Full Text] [Related]
11. Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl.
Iwamura R; Tanaka M; Okanari E; Kirihara T; Odani-Kawabata N; Shams N; Yoneda K
J Med Chem; 2018 Aug; 61(15):6869-6891. PubMed ID: 29995405
[TBL] [Abstract][Full Text] [Related]
12. A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6).
Olander KW; Sato MA; Abrams MA; Jerkins GW; Lu F; Dinh P; Odani-Kawabata N; Chabi A; Shams NK
J Glaucoma; 2021 Jun; 30(6):473-480. PubMed ID: 33813559
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Patient Tolerability of Omidenepag Isopropyl in the Treatment of Glaucoma and Ocular Hypertension.
Matsuo M; Matsuoka Y; Tanito M
Clin Ophthalmol; 2022; 16():1261-1279. PubMed ID: 35510270
[TBL] [Abstract][Full Text] [Related]
14. Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan.
Nakazawa T; Takahashi K; Kuwayama Y; Nomura A; Shimada F
Adv Ther; 2022 Mar; 39(3):1359-1374. PubMed ID: 35072890
[TBL] [Abstract][Full Text] [Related]
15. Cystoid Macular Edema Associated with Omidenepag Isopropyl in Phakic Eyes after Laser Iridotomy: A Case Report.
Nakamoto K; Shiratori N; Nishio Y; Sugimoto S; Takano Y; Yamazaki M; Tobita Y; Igarashi T; Takahashi H
J Nippon Med Sch; 2021 Nov; 88(5):506-508. PubMed ID: 33692292
[TBL] [Abstract][Full Text] [Related]
16. Newly or switching effect of a selective EP2 agonist on intraocular pressure in Japanese patients with open-angle glaucoma.
Ueda K; Sakata R; Fujishiro T; Honjo M; Shirato S; Aihara M
Jpn J Ophthalmol; 2022 Sep; 66(5):434-439. PubMed ID: 35906503
[TBL] [Abstract][Full Text] [Related]
17. Effects of the Selective EP2 Receptor Agonist Omidenepag on Adipocyte Differentiation in 3T3-L1 Cells.
Yamamoto Y; Taniguchi T; Inazumi T; Iwamura R; Yoneda K; Odani-Kawabata N; Matsugi T; Sugimoto Y; Shams NK
J Ocul Pharmacol Ther; 2020 Apr; 36(3):162-169. PubMed ID: 31934812
[No Abstract] [Full Text] [Related]
18. The Antiglaucoma Agent and EP2 Receptor Agonist Omidenepag Does Not Affect Eyelash Growth in Mice.
Esaki Y; Katsuta O; Kamio H; Noto T; Mano H; Iwamura R; Yoneda K; Odani-Kawabata N; Morishima K; Shams NK
J Ocul Pharmacol Ther; 2020 Sep; 36(7):529-533. PubMed ID: 32412835
[No Abstract] [Full Text] [Related]
19. Twenty-Four-Hour Intraocular Pressure Control with Omidenepag Isopropyl 0.002% in Patients with Glaucoma and Ocular Hypertension.
Shiratori N; Nishio Y; Takeda A; Sugimoto S; Takazawa K; Otsuka N; Ishida N; Shii D; Hori K; Nakamoto K
Clin Ophthalmol; 2021; 15():3997-4003. PubMed ID: 34675468
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of early medication persistence with omidenepag isopropyl, a topical selective prostaglandin EP2 agonist, in patients with glaucoma: a retrospective two-institute study.
Nakakura S; Kanamori A; Fukuma Y; Wakabayashi S; Nagata Y; Adachi M
BMJ Open; 2021 Jan; 11(1):e040301. PubMed ID: 33514572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
